Rockefeller Capital Management
AIM

Rockefeller Capital Management’s AIM ImmunoTech AIM Stock Holding History

Rockefeller Capital Management’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-400
Closed -$17K – 2090
2023
Q1 		$17K Hold
400
– – ﹤0.01% 1947
2022
Q4 		$12K Hold
400
– – ﹤0.01% 3028
2022
Q3 		$23K Hold
400
– – ﹤0.01% 2722
2022
Q2 		$31K Hold
400
– – ﹤0.01% 2509
2022
Q1 		$42K Hold
400
– – ﹤0.01% 2382
2021
Q4 		$36K Hold
400
– – ﹤0.01% 2363
2021
Q3 		$80K Hold
400
– – ﹤0.01% 1956
2021
Q2 		$86K Hold
400
– – ﹤0.01% 1858
2021
Q1 		$90K Buy
400
+200
+100% +$45.2K ﹤0.01% 1655
2020
Q4 		$35K Hold
200
– – ﹤0.01% 1804
2020
Q3 		$43K Buy
+200
New +$50K ﹤0.01% 1554

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rockefeller Capital Management's AIM Position: Q2 2023 in Review

Rockefeller Capital Management sold out of AIM ImmunoTech (AIM) in Q2 2023, closing a stake of 400 shares — an estimated $17K sold.

Rockefeller Capital Management first reported a position in AIM in Q3 2020 and held it in 11 quarters. The position peaked at $90K in Q1 2021. 30 funds tracked by Wall St. Rank hold AIM as of Q2 2023.

  • Rockefeller Capital Management reported no remaining AIM ImmunoTech position as of Q2 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 400 AIM ImmunoTech shares in Q2 2023, an estimated $17K.
  • Rockefeller Capital Management first reported a position in AIM ImmunoTech in Q3 2020 and held it in 11 quarters.
  • Rockefeller Capital Management's AIM ImmunoTech position peaked at $90K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2023.

Based on Rockefeller Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.